cellular
• increased proliferation of np396+ CD8+ T cells after LCMV C13 infection as compared to wild type
|
immune system
• increased proliferation of np396+ CD8+ T cells after LCMV C13 infection as compared to wild type
|
• 10 fold increase in the number of LCMV-specific np396+ CD8+ T cells following infection with LCMV clone 13 (C13) as compared to controls
|
• 4 fold increase in number of LCMV Armstrong-specific central memory T CD8+ cells in spleen 70 days after infection
|
• increase in CD44hi CD4+ and CD8+ T cells following LCMV C13 infection
|
• 10 fold increase in secondary cytotoxic T lymphocytes following second dose of LCMV Armstrong as compared to wild type
|
• increased specific CTL lysis as compared to wild type following infection with LCMV clone 13
|
• increased production of interferon gamma following LCMV C13 infection
|
• mice die from LCMV C13 infection after 14 days; wild-type mice survive
|
hematopoietic system
• increased proliferation of np396+ CD8+ T cells after LCMV C13 infection as compared to wild type
|
• 10 fold increase in the number of LCMV-specific np396+ CD8+ T cells following infection with LCMV clone 13 (C13) as compared to controls
|
• 4 fold increase in number of LCMV Armstrong-specific central memory T CD8+ cells in spleen 70 days after infection
|
• increase in CD44hi CD4+ and CD8+ T cells following LCMV C13 infection
|
• 10 fold increase in secondary cytotoxic T lymphocytes following second dose of LCMV Armstrong as compared to wild type
|
• increased specific CTL lysis as compared to wild type following infection with LCMV clone 13
|
mortality/aging
• mice die from LCMV C13 infection after 14 days; wild-type mice survive
|
neoplasm
• decreased number of lung tumors following challenge with B16 F10 melanoma cells as compared to wild type
|
respiratory system
• decreased number of lung tumors following challenge with B16 F10 melanoma cells as compared to wild type
|